Benzoxazole/benzothiazole-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluations.
Antineoplastic Agents
/ chemical synthesis
Benzoxazoles
/ chemistry
Cell Survival
/ drug effects
Drug Design
HCT116 Cells
Hep G2 Cells
Humans
Inhibitory Concentration 50
MCF-7 Cells
Molecular Docking Simulation
Molecular Structure
Structure-Activity Relationship
Thiadiazoles
/ chemistry
Vascular Endothelial Growth Factor Receptor-2
/ antagonists & inhibitors
VEGFR-2 inhibitors
anticancer agents
benzothiazole
benzoxazole
molecular docking
Journal
Archiv der Pharmazie
ISSN: 1521-4184
Titre abrégé: Arch Pharm (Weinheim)
Pays: Germany
ID NLM: 0330167
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
20
06
2019
revised:
29
08
2019
accepted:
01
09
2019
pubmed:
10
10
2019
medline:
21
4
2020
entrez:
10
10
2019
Statut:
ppublish
Résumé
A novel series of benzoxazole/benzothiazole derivatives 4a-c-11a-e were designed, synthesized, and evaluated for anticancer activity against HepG2, HCT-116, and MCF-7 cells. HCT-116 was the most sensitive cell line to the influence of the new derivatives. In particular, compound 4c was found to be the most potent derivative against HepG2, HCT-116, and MCF-7 cells, with IC
Identifiants
pubmed: 31596514
doi: 10.1002/ardp.201900178
doi:
Substances chimiques
Antineoplastic Agents
0
Benzoxazoles
0
Thiadiazoles
0
benzo-1,2,3-thiadiazole
273-77-8
Vascular Endothelial Growth Factor Receptor-2
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1900178Informations de copyright
© 2019 Deutsche Pharmazeutische Gesellschaft.